参考文献/References:
[1] Campion EW, Glynn RJ, DeLabry LO, et al. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study[J].Am J Med,1987,82
(3):421-426.DOI:10.1016/0002-9343(87)90441-4.
[2] Singh JA, Shah N, Edwards NL. A cross-sectional internet-based patient survey of the management strategies for gout [J]. BMC Complement Altern
Med,2016,16:90.DOI:10.1186/s12906-016-1067-3.
[3] Kusuhara H, Sugiyama Y. ATP-binding cassette, subfamily G(ABCG family)[J].Pflugers Arch,2007,453(5):735-744.DOI:10.1007/s00424-006-0134-x.
[4] Maliepaard M, Scheffer GL, FaneyteI F, et al.Subcellular localization and distribution of the breast cancer resistance protein transporter in
normal human tissues[J].Cancer Res,2001,61(8):3458-3464.DOI:10.1016/S0165-4608(00)00403-9.
[5] Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene(ABCP)on chromosome 4q22 that is involved in
multidrug resistance[J].Cancer Res,1998,58(23):5337-5339.DOI:10.1016/j.bbmt.2014.11.496.
[6] Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J].Proc Natl Acad Sci U S A,1998,95
(26):15665-15670.DOI:10.1073/pnas.95.26.15665.
[7] Stiburkova B, Pavelcova K, Zavada J, et al.Functional non-synonymous variants of ABCG2 and gout risk[J].Rheumatology(Oxford),2017,56(11):1982-
1992.DOI:10.1093/rheumatology/kex295.
[8] Fujita K,Ichida K. ABCG2 as a therapeutic target candidate for gout[J].Expert Opin Ther Targets,2018,22(2):123-
129.DOI:10.1080/14728222.2018.1420167.
[9] Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout[J].Proc
Natl Acad Sci U S A,2009,106(25):10338-10342.DOI: 10.1073/pnas.0901249106.
[10] Torres RJ, de Miguel E, Bailen R, et al. Tubular uratetransporter gene polymorphisms differentiate patients with gout who have normal and
decreased urinary uric acid excretion[J].J Rheumatol,2014,41(9):1863-1870.DOI:10.3899/jrheum.140126.
[11] Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels:analysis of association with gout[J].Ann
Rheum Dis,2016,75(1):124-130.DOI:10.1136/annrheumdis-2014-205877.
[12] Major TJ, Dalbeth N, Stahl EA, et al. An update on the genetics of hyperuricaemia and gout[J].Nat Rev Rheumatol,2018,14(6):351-
353.DOI:10.1038/s41584-018-0004-x.
[13] Stiburkova B, Miyata H, Závada J, et al. Novel dysfunctional variant in ABCG2 as a cause of severe tophaceous gout:biochemical,molecular genetics
and functional analysis[J].Rheumatology,2016, 55(1):191-194.DOI:10.1093/rheumatology/kev350.
[14] Horváthová V, Bohatá J, Pavlíková M, et al. Interaction of the p.Q141K variant of the ABCG2 gene with clinical data and cytokine levels in
primary hyperuricemia and gout[J].J Clin Med,2019,8(11):1965.DOI:10.3390/jcm8111965.
[15] Sakiyama M, Matsuo H, Takada Y, et al. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2(ABCG2/BCRP):genotype
combinations and estimated functions[J].Drug Metab Pharmacokinet,2014,29(6):490-492.DOI:10.2133/dmpk.DMPK-14-SC-041.
[16] Stiburkova B, Pavelcova K, Pavlikova M, et al. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset
patients[J].Arthritis Res Ther,2019,21(1):77.DOI:10.1186/s13075-019-1860-8.
[17] Zhang K, Li C. ABCG 2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of
a Chinese Han male population[J].Hereditas,2019,156:26.DOI:10.1186/s41065-019-0103-y.
[18] Higashino T, Takada T, Nakaoka H, et al. Multiple common and rare variants of ABCG2 cause gout[J].RMD Open,2017,3
(2):e000464.DOI:10.1136/rmdopen-2017-000464.
[19] Duong NT, Ngoc NT, Thang NTM, et al. Polymorphisms of ABCG2 and SLC22A12 genes associated with gout risk in Vietnamese population[J].Medicina
(Kaunas),2019,55(1):8.DOI:10.3390/medicina55010008.
[20] Cheng ST, Wu S, Su CW, et al. Association of ABCG2 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han Taiwanese
population[J].J Formos Med Assoc,2017,116(1):18-23.DOI:10.1016/j.jfma.2015.12.002.
[21] Zhou D, Liu Y, Zhang X, et al. Functional polymorphisms of the ABCG2 gene are associated with gout disease in the Chinese Han male population
[J].Int J Mol Sci,2014,15(5):9149-9159.DOI:10.3390/ijms15059149.
[22] Tu HP, Ko AM, Chiang SL, et al. Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk[J].J Rheumatol,2014,41
(4):749-758.DOI:10.3899/jrheum.130870.
[23] Li Z, Zhou Z, Hou X, et al. Replication of gout/urate concentrations GWAS susceptibility loci associated with gout in a Han Chinese population
[J].Sci Rep,2017,7(1):4094. DOI:10.1038/s41598-017-04127-4.
[24] Toyoda Y, Mancˇíková A, Krylov V, et al. Functional characterization of clinically-relevant rare variants in ABCG2 identified in
a gout and hyperuricemia cohort[J].Cells, 2019,8(4):363.DOI:10.3390/cells8040363.
[25] Toyoda Y, Pavelcová K, Klein M, et al. Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in
urate transporter ABCG2[J].Arthritis Res Ther,2019,21(1):219.DOI:10.1186/s13075-019-2007-7.
[26] Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of function polymorphism predicts poor response to allopurinol in patients with gout
[J].Pharmacogenomics J,2017,17(2):201-203.DOI:10.1038/tpj.2015.101.
[27] Stamp LK, Chapman PT, Barclay M, et al. Relationships between allopurinol dose, oxypurinol concentration and urate lowering response in search of
a minimum effective oxypurinol concentration[J].Clin Transl Sci,2020,13(1):110-115.DOI:10.1111/cts.12686.
[28] Stamp LK, Wallace M, Roberts RL, et al. ABCG2 rs2231142(Q141K)and oxypurinol concentrations in people with gout receiving allopurinol[J].Drug
Metab Pharmacokinet,2018,33(6):241-242.DOI:10.1016/j.dmpk.2018.09.002.
[29] Wallace MC, Roberts RL, Nanavati P, et al. Association between ABCG2 rs2231142 and poor response to allopurinol:replication and meta-analysis
[J].Rheumatology(Oxford),2018,57(4):656-660.DOI:10.1093/rheumatology/kex467.
[30] Nakamura M, Fujita K, Toyoda Y, et al. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2[J].Drug
Metab Pharmacokinet,2018,33(1):77-81.DOI:10.1016/j.dmpk.2017.11.002.
[31] Stamp LK, Topless R, Miner JN, et al. No association between ATP-binding cassette transporter G2 rs2231142(Q141K)and urate-lowering response to
febuxostat[J].Rheumatology(Oxford),2019,58(3):547-548.DOI:10.1093/rheumatology/key423.